MX366955B - Crlx101 para usarse en el tratamiento de cáncer. - Google Patents

Crlx101 para usarse en el tratamiento de cáncer.

Info

Publication number
MX366955B
MX366955B MX2016013249A MX2016013249A MX366955B MX 366955 B MX366955 B MX 366955B MX 2016013249 A MX2016013249 A MX 2016013249A MX 2016013249 A MX2016013249 A MX 2016013249A MX 366955 B MX366955 B MX 366955B
Authority
MX
Mexico
Prior art keywords
cancer
treatment
cdp
camptothecin
crlx101
Prior art date
Application number
MX2016013249A
Other languages
English (en)
Inventor
Davis Mark
Yen Yun
Schluep Thomas
Ryan John
C Oliver James
Original Assignee
Bluelink Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bluelink Pharmaceuticals Inc filed Critical Bluelink Pharmaceuticals Inc
Publication of MX366955B publication Critical patent/MX366955B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un conjugado de polímero que contiene ciclodextrina (CDP)-inhibidor de topoisomerasa para usarse en un método de tratamiento de cáncer en un individuo, en donde el método comprende: proveer una administración inicial de dicho conjugado de CDP-inhibidor de topoisomerasa a dicho individuo a una dosificación de 12 mg/m2, 13 mg/m2, 14 mg/m2 o 15 mg/m2, en donde dicho dosificación se expresa en mg de inhibidor de topoisomerasa, en oposición a mg de conjugado; y proveer más de una administración subsecuente de dicho conjugado de CDP-inhibidor de topoisomerasa a una dosificación de 12 mg/m2, 13 mg/m2, 14 mg/m2 o 15 mg/m2, en donde cada administración subsecuente se proporciona, independientemente, entre 12, 13, 14, 15 o 16 días después de la administración preveía: en donde el método comprende administrar dicho conjugado de CDP-inhibidor de topoisomerasa en combinación con uno o más agentes terapéuticos adicionales: en donde el conjugado de CDP-inhibidor de topoisomerasa es un conjugado de CDP-camptotecina ; y en donde le conjugado de CDP-camptotecina es CRLX101.
MX2016013249A 2009-09-15 2010-09-15 Crlx101 para usarse en el tratamiento de cáncer. MX366955B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24275209P 2009-09-15 2009-09-15
US31703910P 2010-03-24 2010-03-24
US33215010P 2010-05-06 2010-05-06
US38185110P 2010-09-10 2010-09-10
PCT/US2010/048973 WO2011034954A1 (en) 2009-09-15 2010-09-15 Treatment of cancer

Publications (1)

Publication Number Publication Date
MX366955B true MX366955B (es) 2019-07-31

Family

ID=43758997

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012003046A MX342709B (es) 2009-09-15 2010-09-15 Tratamiento contra el cancer.
MX2016013249A MX366955B (es) 2009-09-15 2010-09-15 Crlx101 para usarse en el tratamiento de cáncer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012003046A MX342709B (es) 2009-09-15 2010-09-15 Tratamiento contra el cancer.

Country Status (11)

Country Link
US (5) US20110160159A1 (es)
EP (1) EP2477985B1 (es)
JP (6) JP5855568B2 (es)
CN (1) CN102666533A (es)
AU (1) AU2010295646B2 (es)
BR (1) BR112012005594A2 (es)
CA (2) CA2939165A1 (es)
EA (1) EA201200486A1 (es)
IL (1) IL218575A0 (es)
MX (2) MX342709B (es)
WO (1) WO2011034954A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
EP2402036B1 (en) 2002-09-06 2018-02-14 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently attached thereto
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
MY164086A (en) 2009-10-29 2017-11-30 Aventis Pharma Sa Novel antitumoral use of cabazitaxel
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US20140105891A1 (en) * 2012-10-05 2014-04-17 Cerulean Pharma Inc. Treatment of cancer
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
KR102356017B1 (ko) 2012-12-13 2022-01-27 이뮤노메딕스, 인코오포레이티드 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
MA38349A1 (fr) 2013-02-21 2017-02-28 Bayer Pharma AG Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
EP2801370A1 (en) * 2013-05-07 2014-11-12 Fundació Privada Institut d'Investigació Oncològica de Vall Hebron Methods and compositions for the treatment of cancer
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3049078B1 (en) * 2013-09-27 2018-06-27 BlueLink Pharmaceuticals, Inc. Treatment of cancer
EP3096752A4 (en) * 2014-01-24 2017-10-18 Sirtex Medical Limited Treatment of neoplasia
US20180028531A1 (en) * 2015-02-12 2018-02-01 BeyondSpring Phamaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
RU2736045C2 (ru) 2015-03-06 2020-11-11 Бейондспринг Фармасьютикалс, Инк. Способ лечения рака, ассоциированного с мутацией ras
CA2981543A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017011399A1 (en) 2015-07-13 2017-01-19 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
SI3337467T1 (sl) 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
FR3040860B1 (fr) * 2015-09-10 2020-05-15 Universite de Bordeaux Milieu de conservation injectable pour la conservation de cellules du sang placentaire, de la moelle osseuse et du sang peripherique
CN109195590A (zh) * 2015-11-03 2019-01-11 纳米珀特伊根公司 聚合纳米颗粒
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CA3011372A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
WO2017177055A1 (en) * 2016-04-08 2017-10-12 Liang Zhao Cyclodextrin-based polymers for therapeutic delivery
US10266605B2 (en) 2016-04-27 2019-04-23 Immunomedics, Inc. Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
BR112018074990A2 (pt) 2016-06-06 2019-03-12 Beyondspring Pharmaceuticals, Inc. composição, usos e método para reduzir neutropenia
US20200093932A1 (en) * 2016-12-01 2020-03-26 Bluelink Pharmaceuticals, Inc. Treatment of cancer
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
CA3050332A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
MX2020012799A (es) * 2018-06-01 2021-03-25 Beyondspring Pharmaceuticals Inc Composicion y metodo para tratar el cancer asociado con mutacion del egfr.
IL308722A (en) 2018-10-17 2024-01-01 Biolinerx Ltd Treatment of metastatic adenocarcinoma of the pancreas
EP3911353A1 (en) 2019-01-17 2021-11-24 BioLineRx Ltd. Specific combination therapy for treatment of pancreatic cancer
WO2020148744A1 (en) 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
WO2021119464A1 (en) * 2019-12-13 2021-06-17 Veri Nano Inc. Compositions and modular nano- and microparticles for the delivery of various agents and use thereof
US20220218687A1 (en) * 2021-01-08 2022-07-14 Starton Therapeutics, Inc. Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use
CN115109258A (zh) * 2021-03-19 2022-09-27 江西中医药大学 7-乙基-10-羟基喜树碱聚合物、制备方法及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
ES2058081T3 (es) 1986-09-05 1994-11-01 American Cyanamid Co Poliesteres que contienen bloques de oxido de alquileno como sistemas de administracion de medicamentos.
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
FR2665169A1 (fr) 1990-07-30 1992-01-31 Rhone Poulenc Chimie Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres.
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
WO2000023096A2 (en) * 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Combination therapy with vip antagonist
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
AUPP913999A0 (en) * 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
US7008936B2 (en) * 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
EP2402036B1 (en) * 2002-09-06 2018-02-14 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently attached thereto
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7358262B2 (en) * 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
CN1216057C (zh) * 2003-03-28 2005-08-24 贵州省生物研究所 喜树碱类似物的衍生物及其制备方法
CA2547934C (en) * 2004-02-19 2013-05-21 Abbott Laboratories Methods of using gamma cyclodextrin to control blood glucose and insulin secretion
ES2564127T5 (es) * 2004-06-04 2020-03-26 Genentech Inc Mutaciones en EGFR
TW200640493A (en) * 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
US20090202989A1 (en) * 2005-06-28 2009-08-13 Hillan Kenneth J Egfr and kras mutations
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
US20110177161A1 (en) * 2007-05-24 2011-07-21 Dr. Reddy's Laboratories Limited Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
EA201171195A8 (ru) * 2009-03-30 2014-08-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer

Also Published As

Publication number Publication date
JP5855568B2 (ja) 2016-02-09
AU2010295646B2 (en) 2016-02-11
EP2477985B1 (en) 2018-11-07
BR112012005594A2 (pt) 2015-09-08
US20160058875A1 (en) 2016-03-03
EA201200486A1 (ru) 2012-08-30
WO2011034954A1 (en) 2011-03-24
JP2020164547A (ja) 2020-10-08
US20130338103A1 (en) 2013-12-19
EP2477985A4 (en) 2013-05-15
JP2022166327A (ja) 2022-11-01
EP2477985A1 (en) 2012-07-25
JP2013504630A (ja) 2013-02-07
JP2015025020A (ja) 2015-02-05
MX2012003046A (es) 2012-09-07
IL218575A0 (en) 2012-05-31
JP2016106143A (ja) 2016-06-16
CA2939165A1 (en) 2011-03-24
AU2010295646A1 (en) 2012-04-05
CA2774015A1 (en) 2011-03-24
JP2017226708A (ja) 2017-12-28
CN102666533A (zh) 2012-09-12
US20110160159A1 (en) 2011-06-30
MX342709B (es) 2016-10-10
US20130164282A1 (en) 2013-06-27
US20180071404A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
MX342709B (es) Tratamiento contra el cancer.
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
SG10201407927UA (en) Imidazopyridine derivatives as jak inhibitors
NZ597517A (en) 5-fluoropyrimidinone derivatives
GEP201706688B (en) Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
RS20120461A1 (en) METHODS FOR STIMULATION OF LIVER REGENERATION
IN2012DN00971A (es)
IN2012DN03182A (es)
MX2011003738A (es) Conjugados hpma-docetaxel o gemcitabine y sus usos asociados.
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
EP2331520A4 (en) ROSAMINE DERIVATIVES AS AGENTS FOR CANCER TREATMENT
WO2011020107A3 (en) Compositions and methods for detection and treatment of breast cancer
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
WO2012162513A3 (en) Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors
MX2011008195A (es) Derivados de indol como agentes anticancer.
IN2012DN03404A (es)
HK1124842A1 (en) Methods of preparing imidazole-based compounds
MX2009008249A (es) Composicion farmaceutica que comprende derivado de camptotecina.
EP2528440A4 (en) SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF